Skip to main content

Table 2 Second-Line Treatment Regimens in the Chemotherapy Group (n = 89)

From: Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Second-Line Therapy Received, n (%)  
Gemcitabine 28 (31.5)
Vinorelbine 24 (26.9)
Docetaxel 22 (24.7)
Others 7 (7.9)
Carboplatin/gemcitabine 2 (2.2)
Atezolizumab 2 (2.2)
Carboplatin/docetaxel 2 (2.2)
Carboplatin/vinorelbine 1 (1.1)
Pembrolizumab/docetaxel 1 (1.1)